RASC’s Substack

RASC’s Substack

Share this post

RASC’s Substack
RASC’s Substack
VHI.TO Q4 2024 & Business Review Update

VHI.TO Q4 2024 & Business Review Update

RASC Investing's avatar
RASC Investing
Mar 28, 2025
∙ Paid

Share this post

RASC’s Substack
RASC’s Substack
VHI.TO Q4 2024 & Business Review Update
Share

Overall

Vitalhub continues its “up and to the right” operating performance all at low levels of business risk

  • Leading the pack amongst all Canadian listed software consolidators with organic growth on recurring revenue of 15% over the TTM period

  • Management remains bullish on 2025 outlook both in terms of organic free cash flow growth through further organic revenue growth and cost optimization on new acquisition plus a growing M&A pipeline which their balance sheet allows them to take advantage of

  • Can play offence to buy up weaker players that don't have their balance sheet or operating playbook to drive profitability

  • High predictability and profitability (recurring revenue model, sticky solution via high switching costs resulting in low customer churn) - As "recession proof" of a product as it gets (health tech to public health agencies)

  • Rock solid balance sheet with no debt and a war chest of Cash ($90M in Cash with $155M in total liquidity)

  • Positive demographic trends (i.e. aging population driving healthcare demand, public health agencies need tech to meet demand)

  • Founders and Board with skin in the game

Below I provide my thoughts on:

  • Quarterly financial performance

  • Vitalhub Innovations Labs

  • Impact of Tariffs

  • M&A Update

  • Balance Sheet & Liquidity to Support Growth

  • Business Risk Summary

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 RASC Investing
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share